Found: 34
Select item for more details and to access through your institution.
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
- Published in:
- British Journal of Haematology, 2020, v. 188, n. 6, p. 907, doi. 10.1111/bjh.16287
- By:
- Publication type:
- Article
Correlation between burden of 17 P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
- Published in:
- British Journal of Haematology, 2013, v. 162, n. 4, p. 555, doi. 10.1111/bjh.12385
- By:
- Publication type:
- Article
Long Term Evaluation of the Impact of Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: A Cost-Effectiveness Analysis.
- Published in:
- PLoS ONE, 2013, v. 8, n. 9, p. 1, doi. 10.1371/journal.pone.0075047
- By:
- Publication type:
- Article
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).
- Published in:
- Annals of Hematology, 2019, v. 98, n. 2, p. 361, doi. 10.1007/s00277-018-3524-1
- By:
- Publication type:
- Article
Clinical efficacy of arsenic trioxide in a patient with acute promyelocytic leukemia with recurrent central nervous system involvement.
- Published in:
- 2011
- By:
- Publication type:
- Letter
Mucocutaneous paraneoplastic syndromes in hematologic malignancies.
- Published in:
- International Journal of Dermatology, 2006, v. 45, n. 1, p. 14, doi. 10.1111/j.1365-4632.2005.02668.x
- By:
- Publication type:
- Article
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
- Published in:
- European Journal of Haematology, 2022, v. 108, n. 1, p. 73, doi. 10.1111/ejh.13706
- By:
- Publication type:
- Article
Serum CA 125 is of clinical value in the staging and follow-up of patients with non-hodgkin's lymphoma.
- Published in:
- Cancer (0008543X), 1998, v. 82, n. 3, p. 576, doi. 10.1002/(SICI)1097-0142(19980201)82:3<576::AID-CNCR21>3.0.CO;2-Y
- By:
- Publication type:
- Article
The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Clinical results in 46 patients.
- Published in:
- 1993
- By:
- Publication type:
- journal article
Monoclonal gammopathy of undetermined significance: a new proposal of workup.
- Published in:
- European Journal of Haematology, 2013, v. 91, n. 4, p. 356, doi. 10.1111/ejh.12172
- By:
- Publication type:
- Article
Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived.
- Published in:
- European Journal of Haematology, 2009, v. 83, n. 5, p. 449, doi. 10.1111/j.1600-0609.2009.01295.x
- By:
- Publication type:
- Article
Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients.
- Published in:
- 2009
- By:
- Publication type:
- Letter
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts.
- Published in:
- European Journal of Haematology, 2009, v. 82, n. 2, p. 93, doi. 10.1111/j.1600-0609.2008.01179.x
- By:
- Publication type:
- Article
Thrombomodulin levels are not modified during thalidomide treatment.
- Published in:
- 2006
- By:
- Publication type:
- Letter
Limited Feasibility of Double Transplant in Multiple Myeloma.
- Published in:
- Cancer (0008543X), 2007, v. 109, n. 11, p. 2273, doi. 10.1002/cncr.22660
- By:
- Publication type:
- Article
Zoledronic acid down‐regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: A possible mechanism for its antitumor effect.
- Published in:
- Cancer (0008543X), 2005, v. 104, n. 1, p. 118, doi. 10.1002/cncr.21104
- By:
- Publication type:
- Article
Pomalidomide + Bortezomib + Dexamethasone After One Prior Line of Therapy in Bortezomib-Pretreated Multiple Myeloma: Subanalysis of OPTIMISMM.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e32, doi. 10.1016/j.clml.2019.09.048
- By:
- Publication type:
- Article
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Resolution of invasive fungal sinusitis in immunocompromised patients: neutrophil count is crucial beside a combined medical and surgical approach.
- Published in:
- 2010
- By:
- Publication type:
- Letter
Severe intestinal vasculitis in a patient under treatment with bortezomib.
- Published in:
- 2007
- By:
- Publication type:
- Letter
Late onset of bortezomib-associated cutaneous reaction following herpes zoster.
- Published in:
- 2007
- By:
- Publication type:
- Letter
Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia: a single center experience.
- Published in:
- 2001
- By:
- Publication type:
- journal article
DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients.
- Published in:
- Transfusion, 2008, v. 48, n. 5, p. 857, doi. 10.1111/j.1537-2995.2007.01621.x
- By:
- Publication type:
- Article
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 6, p. 575, doi. 10.1002/ajh.24351
- By:
- Publication type:
- Article
Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.
- Published in:
- American Journal of Hematology, 2013, v. 88, n. 2, p. 102, doi. 10.1002/ajh.23358
- By:
- Publication type:
- Article
Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma.
- Published in:
- American Journal of Hematology, 2012, v. 87, n. 2, p. 150, doi. 10.1002/ajh.22220
- By:
- Publication type:
- Article
Emergent T-helper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain.
- Published in:
- 2010
- By:
- Publication type:
- Letter
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
- Published in:
- British Journal of Haematology, 2009, v. 144, n. 2, p. 169, doi. 10.1111/j.1365-2141.2008.07409.x
- By:
- Publication type:
- Article
The natural history of a solitary plasmacytoma.
- Published in:
- British Journal of Haematology, 2002, v. 118, n. 2, p. 350, doi. 10.1046/j.1365-2141.2002.03629.x
- By:
- Publication type:
- Article
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis.
- Published in:
- British Journal of Haematology, 2002, v. 116, n. 4, p. 855, doi. 10.1046/j.0007-1048.2002.03367.x
- By:
- Publication type:
- Article
Experts’ consensus on the definition and management of high risk multiple myeloma.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2022.1096852
- By:
- Publication type:
- Article
Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia.
- Published in:
- Oncology & Therapy, 2021, v. 9, n. 1, p. 139, doi. 10.1007/s40487-020-00137-x
- By:
- Publication type:
- Article
The smell of bare death: Encountering life at the graveyard of Lampedusa.
- Published in:
- Anthropological Theory, 2023, v. 23, n. 3, p. 332, doi. 10.1177/14634996221128104
- By:
- Publication type:
- Article
Modulation of all-trans retinoid acid pharmacokinetics in acute promyelocytic leukaemia by prolonged interferon-α therapy.
- Published in:
- British Journal of Haematology, 1995, v. 90, n. 4, p. 928, doi. 10.1111/j.1365-2141.1995.tb05217.x
- By:
- Publication type:
- Article